Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y238
UPID:
DLEC1_HUMAN
Alternative names:
Deleted in lung cancer protein 1
Alternative UPACC:
Q9Y238; Q9NSW0; Q9NTG5
Background:
Deleted in lung and esophageal cancer protein 1, alternatively known as Deleted in lung cancer protein 1, plays a pivotal role in spermatogenesis and male fertility. It is implicated in the formation of sperm head and tail, suggesting its crucial involvement in reproductive biology. Moreover, its function as a tumor suppressor, inhibiting cell proliferation, underscores its significance in cellular regulation.
Therapeutic significance:
The involvement of Deleted in lung and esophageal cancer protein 1 in lung and esophageal cancers, through DLEC1 silencing due to promoter methylation and aberrant transcription, highlights its potential as a therapeutic target. Understanding the role of this protein could open doors to potential therapeutic strategies, offering hope for improved treatment options for these devastating malignancies.